Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201208004 Principal Investigator: Linette, Gerald
Title: A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (stage IIIc) or metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma
Phase: III Disease Site: Melanoma, Skin
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this research study is to test the safety of dabrafenib and trametinib to see how well they work together compared to another drug, vemurafenib. The effects of the drugs, both good and bad, will be compared.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)